Health Boards
Creabilis raised €15 million (about $20 million) in a Series B round of fundraising led by Abbott Biotech Ventures. The funds will be used to support continuing development of the firm’s lead product CT327 to the end of Phase II trials, along with additional pipeline candidates.
CT327 is a topical TrkA kinase inhibitor which is currently undergoing Phase II clinical trials in psoriasis and atopic dermatitis, and proof-of-concept studies in pain. The candidate has been developed using Creabilis’s Low Systemic Exposure (LSE) platform for conjugating small molecules to low molecular weight polyoxyethylene. The firm claims the LSE technology results in products with high local and low systemic exposures, and optimizes drug molecules for topical routes of administration.
Creabilis’s pipeline includes a second, LSE-modified TrkA kinase inhibitor, CT340, which is preclinical development for psoriasis and atopic dermatitis, and also for other indications including inflammatory aritis and pain. The firm says it anticipates filing an IND application in 2012.
A second preclinical-stage candidate, CT637, is a PEGylated variant of HMGB-1 Box-A domain targeting Toll-like receptors (TLRs), which is in development for the treatment of inflammatory and autoimmune diseases. Creabilis’s research-stage CT750 program is centred on the development of LSE-modified local anaesthetics for the treatment of pain, which demonstrate low systemic exposure and thus reduced risk of cardiotoxicity.
Source: genengnews.com
CT327 is a topical TrkA kinase inhibitor which is currently undergoing Phase II clinical trials in psoriasis and atopic dermatitis, and proof-of-concept studies in pain. The candidate has been developed using Creabilis’s Low Systemic Exposure (LSE) platform for conjugating small molecules to low molecular weight polyoxyethylene. The firm claims the LSE technology results in products with high local and low systemic exposures, and optimizes drug molecules for topical routes of administration.
Creabilis’s pipeline includes a second, LSE-modified TrkA kinase inhibitor, CT340, which is preclinical development for psoriasis and atopic dermatitis, and also for other indications including inflammatory aritis and pain. The firm says it anticipates filing an IND application in 2012.
A second preclinical-stage candidate, CT637, is a PEGylated variant of HMGB-1 Box-A domain targeting Toll-like receptors (TLRs), which is in development for the treatment of inflammatory and autoimmune diseases. Creabilis’s research-stage CT750 program is centred on the development of LSE-modified local anaesthetics for the treatment of pain, which demonstrate low systemic exposure and thus reduced risk of cardiotoxicity.
Source: genengnews.com